Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BK-specific cytotoxic T-lymphocytes
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
BK-specific cytotoxic T-lymphocytes (BK CTLs) is an adoptive cell therapy being developed by New York Medical College for the treatment of refractory BK virus infection in immunocompromised patients, particularly children, adolescents, and young adults following allogeneic hematopoietic stem cell transplantation (allo-HSCT) or solid organ transplantation. The therapy consists of donor-derived T cells that are manufactured using the IFN-γ Cytokine Capture System automated on the CliniMACS Prodigy device. These T cells are specifically selected to target BK virus antigens, including the large T antigen (TAg) and viral capsid protein 1 (VP1). By infusing these virus-specific T cells, the therapy aims to restore cellular immunity against the BK virus and facilitate viral clearance in patients who have failed standard antiviral treatments.
- Other names
- BK virus-specific T cellsBK-specific CTLsRelated Donor BK Specific Cytotoxic T-cells
02
Targets
BK virus VP1 capsid protein-derived peptides presented on MHCBKV LTAg (BK polyomavirus large T antigen)BK polyomavirus small T antigen–derived peptides presented on MHCBK polyomavirus VP2/VP3 capsid protein-derived peptide-MHC complex
Beyond the preview
Go deeper on BK-specific cytotoxic T-lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BK-specific cytotoxic T-lymphocytes.